Business Context and Reporting Period
This Form 8-K Current Report from uniQure N.V. covers the date of October 24, 2018. The filing reports on the results of an Extraordinary General Meeting (EGM) of Shareholders held on that date. The company is incorporated in The Netherlands and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is a corporate governance action regarding the Board of Directors:
- Appointment of Executive Director: Dr. Robert Gut was appointed as an Executive Director effective October 24, 2018.
- Background: Dr. Gut previously served as a non-executive director from June 2018 until his resignation in August 2018 to become the company's Chief Medical Officer. Under Dutch law and the company's Articles of Association, he could not hold both positions simultaneously.
- Voting Results: Of 37,275,199 shares eligible to vote, 21,178,070 were cast. The proposal to appoint Dr. Gut passed with 21,136,091 votes in favor, 39,630 against, and 2,349 abstentions.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, or specific business risks. The document is strictly limited to reporting the shareholder vote outcome and the resulting change in board composition.
Investor Verification Checklist
- Verify the effective date of Dr. Robert Gut's appointment as Executive Director (October 24, 2018).
- Confirm the term of the appointment ends at the 2021 Annual General Meeting.
- Review the company's Articles of Association regarding the restriction on holding simultaneous executive and non-executive director roles.
- Note that this filing does not provide updated financial statements; refer to the most recent 10-K or 10-Q for financial data.